Skip to main content

Site notifications

Australian Public Assessment Reports (AusPAR)

Search our AusPAR dataset.

An AusPAR provides information about the evaluation of a prescription medicine and the considerations that led the TGA to approve or not approve an application.

For more information see Australian Public Assessment Reports for prescription medicines (AusPARs).

Use the filters below to narrow your search.

Filter results

You can narrow down the results using the filters.

1073 result(s) found, displaying 201 to 225
  • New AusPAR for Rholistiq (belumosudil) for the treatment of patients with chronic graft-versus-host disease aged 12 years and older.
  • New AusPAR for Dupixent (dupilumab) for the treatment of atopic dermatitis and chronic rhinosinusitis with nasal polyposis.
  • Australian Public Assessment Report for Lurbinectedin
  • Australian Public Assessment Report for Luspatercept
  • New AusPAR for Venclexta (venetoclax) for acute myeloid leukaemia indication, provisional to full registration.
  • Australian Public Assessment Report for Inclisiran
  • New AusPAR for Ruzurgi (amifampridine) for the treatment of Lambert-Eaton myasthenic syndrome.
  • Australian Public Assessment Report for Tozinameran
  • Forxiga (dapagliflozin) has been approved for reducing the risk of progressive decline in kidney function in adults with
    proteinuric chronic kidney disease.
  • New AusPAR for Trodelvy (sacituzumab govitecan) for the treatment of breast cancer.
  • New AusPAR for Dayvigo (lemborexant) for the treatment of insomnia.
  • New AusPAR for EVUSHELD (tixagevimab and cilgavimab) for pre-exposure prophylaxis of COVID-19 in adults and adolescents aged 12 years older
  • New AusPAR for Vyepti (eptinezumab) for the preventive treatment of migraine in adults.
  • Australian Public Assessment Report for Elasomeran
  • New AusPAR for Vaxzevria (ChAdOx-1-S) for the prevention of COVID-19 caused by SARS-CoV-2
  • Australian Public Assessment Report for Molnupiravir
  • Australian Public Assessment Report for Tozinameran
  • New AusPAR for Abevmy (bevacizumab) for the treatment of various types of cancers.
  • Australian Public Assessment Report for nirmatrelvir/ritonavir
  • New AusPAR for KamRAB (rabies immunoglobulin) for the treatment of passive, transient post-exposure prophylaxis of rabies infection.
  • New AusPAR for ACTEMRA Tocilizumab (rch) for the treatment of coronavirus disease 2019 (COVID-19).

Help us improve this page